ESYA Labs, a lysosomal biology and biomarker discovery company, has entered into a partnership with Alamar Biosciences to advance biomarker detection and diagnostics.
This collaboration aims to transform the detection and quantification of biomarkers for neurological and inflammatory diseases.
It will utilise Alamar’s proprietary NULISA platform and ARGO HT System. These technologies will be available at ESYA Labs’ laboratory in Dallas, Texas.
ESYA Labs will become a certified service provider for Alamar, offering customised assay solutions to support pharmaceutical companies in developing therapeutics for neurological, inflammatory, and neurodegenerative diseases.
These include Alzheimer’s, Parkinson’s, frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other disorders affecting the central and peripheral nervous systems.
The collaboration leverages ESYA’s multi-omics and computational analytics expertise alongside Alamar’s immunoassay technology.
ESYA Labs CEO Dhivya Venkat said: “Our partnership with Alamar marks a milestone in our mission to redefine precision diagnostics.
“By integrating ESYA’s cutting-edge platforms with Alamar’s innovative assay systems, we’re poised to deliver transformative tools for addressing the challenges of neurodegenerative diseases.”
The partnership will create targeted solutions to support the development of the next generation of precision medicine.
It will combine ESYA’s advanced lysosomal biology insights and machine learning diagnostics with Alamar’s ultra-sensitive immunoassay technology.
Alamar Biosciences founder, chairman, and CEO Yuling Luo said: “We are thrilled to partner with ESYA labs.
“The integration of Alamar’s novel NULISA biomarker assays into their multi-omics platform will advance the field of testing for neurodegeneration diseases.”
ESYA Labs specialises in molecular brain health monitoring using DNA nanotechnology and neuro multi-omics platforms, providing actionable insights into Parkinson’s and Alzheimer’s.
Alamar Biosciences is a privately held life sciences company focused on powering precision proteomics for early disease detection.
Its NULISA platform, paired with the ARGO HT System, achieves single-digit attomolar detection sensitivity, surpassing the capabilities of existing protein detection technologies.
In October, the company partnered with ADx NeuroSciences to provide customised blood-based biomarker assay solutions to accelerate biopharma clinical development.
Furthermore, in February, Alamar Biosciences secured $128m in Series C financing to accelerate the commercialisation of its proteomics platform.
